Metachronous multifocal early gastric cancer after partial gastrectomy for synchronous multifocal early gastric cancer: a case report and literature review Authors: Qiang Geng, Qing Yang, Shubei Chen, Wei Qiu, Xiaoling Liu, Changfeng Sun, Cunliang Deng, Ou Jiang Published: 2026 ABSTRACT With the rapid advancement of digestive endoscopy techniques, an increasing number of early gastric cancers (EGCs) have been diagnosed and treated, substantially improving the 5-year survival rate of patients with EGC. Multifocal gastric cancer is a relatively uncommon subtype, and repeated occurrences of multifocal gastric cancer are even less frequently observed. The pathogenesis may involve persistent field cancerization of the background gastric mucosa and, in some patients, an inherited predisposition; evaluation of mismatch repair (MMR) status is an important component of the assessment. Here, we report a young male patient who experienced two episodes of multifocal early gastric cancer over a 9-year period. Both episodes were treated with curative intent—initially by proximal one-third gastrectomy for synchronous multifocal early gastric cancer and subsequently by minimally invasive endoscopic resection for metachronous multifocal early gastric cancer in the remnant stomach. This case suggests that patients with synchronous multifocal early gastric cancer remain at risk for metachronous multifocal gastric cancer even after curative treatment. In particular, among those with high-risk profiles—including a family history of cancer, Helicobacter pylori infection, and gastric mucosal atrophy with intestinal metaplasia—greater emphasis should be placed on high-quality endoscopic screening, long-term surveillance, and genetic susceptibility assessment when indicated. Introduction Gastric cancer is the fifth most common cancer worldwide (1). The main determinant of the 5-year survival rate is the disease stage at diagnosis. Owing to the rapid development and dissemination of endoscopic techniques, the detection of early gastric cancer has markedly increased. Endoscopic resection—including endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD)—has become a standard treatment for selected cases, offering advantages such as minimal invasiveness, preservation of gastric function, and improved postoperative quality of life, thereby reducing the overall medical and socioeconomic burden (2, 3). Currently, the 5-year survival rate for patients with early gastric cancer exceeds 90% (4). Synchronous multifocal gastric cancer, most of which presents as early gastric cancer, is a relatively uncommon subtype and remains under-recognized in clinical practice. However, with the widespread adoption of magnifying endoscopy, electronic chromoendoscopy, and advanced endoscopic treatments, its detection rate has gradually increased (5). Importantly, patients with synchronous multifocal gastric cancer remain at risk of developing metachronous gastric cancer even after curative treatment. Compared with solitary gastric cancer, long-term management of patients with synchronous multifocal gastric cancer is more challenging. In the presence of concurrent risk factors such as H. pylori infection, gastric mucosal atrophy with intestinal metaplasia, a family history of cancer, or a suspected genetic predisposition, meticulous endoscopic examination and long-term surveillance are essential. Herein, we report a young male patient with a family history of colorectal cancer and prior H. pylori infection who underwent proximal one-third gastrectomy for synchronous multifocal early gastric carcinomas. Nine years later, three metachronous early gastric cancer lesions were detected in the remnant stomach and were curatively treated by EMR and ESD. This case illustrates the occurrence of multiple primary cancers that arose at different sites within the same organ over several years and were managed with distinct treatment modalities. It also underscores the need to integrate endoscopic surveillance with timely genetic evaluation in high-risk patients. Case presentation A 38-year-old male presented in 2017 with epigastric pain and underwent diagnostic gastroscopy. He had a history of H. pylori infection. His family history was notable for an elder brother who had died of colon cancer. Gastroscopy revealed two ulcerative lesions located in the gastric fundus and the anterior wall of the upper gastric body, respectively. Targeted biopsies showed high-grade intraepithelial neoplasia. After multidisciplinary discussion, the patient underwent resection of the upper third of the stomach (proximal one-third gastrectomy). Postoperative pathological examination demonstrated two spatially separate lesions with intervening normal gastric mucosa: one in the gastric fundus approximately 8 mm in diameter, and the other in the anterior wall of the upper gastric body approximately 10 mm in diameter. Histopathological examination of both lesions showed high-grade intraepithelial neoplasia. No lymphovascular invasion, perineural invasion, or lymph node metastasis was identified, and there was no extension into surrounding tissues. Resection margins were negative. Both lesions were classified as high-grade intraepithelial neoplasia (HGIN), corresponding to carcinoma in situ (pTis); the final pathological stage was pTisN0M0 (6, 7). In this report, consistent with contemporary clinical practice, the term ‘early gastric cancer’ is used inclusively to encompass both HGIN (carcinoma in situ) and invasive mucosal adenocarcinoma; the 2017 lesions are therefore referred to as synchronous multifocal early gastric cancer (8). The patient recovered uneventfully after surgery and did not receive adjuvant chemotherapy. Following discharge, he underwent H. pylori eradication therapy, and successful eradication was confirmed by a 14C-urea breath test. Thereafter, he underwent annual endoscopic surveillance. In 2026, during routine surveillance gastroscopy at a local hospital, a 0-Is type polyp was identified in the remnant stomach. Biopsy pathology revealed high-grade intraepithelial neoplasia, and the patient was referred to our hospital for further management. On admission, a meticulous gastroscopic examination was performed. Three lesions were detected in the remnant stomach: (i) A 0-Is polyp measuring approximately 7 mm in diameter on the anterior wall of the remnant stomach. Under blue laser imaging (BLI) and magnifying endoscopy (ME), a post-biopsy scar and thickened microvascular structures at the tip of the polyp were observed (Figures 1A, B); (ii) A 0-IIa+IIc lesion measuring approximately 10 mm in diameter on the lesser curvature of the remnant stomach. Under BLI combined with ME, the lesion exhibited a well-demarcated border, with an irregular vascular network and abnormal glandular structures in the central area (Figures 2A–C). Endoscopic ultrasound (EUS) demonstrated an intact muscularis mucosae (Figures 2D); (iii) A 0-IIa+IIc lesion measuring approximately 6 mm in diameter on the lesser curvature of the gastric antrum. Under BLI combined with ME, an abnormal vascular network was observed (Figures 3A, B). EUS also showed an intact muscularis mucosae (Figure 3C). 0-Is polyp on the anterior wall of the remnant stomach. (A) Polypoid lesion under white light imaging. (B) BLI+ME showing a post-biopsy scar and thickened microvessels at the tip. 0-IIa+IIc lesion on the lesser curvature of the remnant stomach. (A) White light imaging shows a superficial elevation with mild central depression. (B, C) BLI+ME showing clear boundaries of the lesion, with irregular microvessels and surface structures visible. (D) EUS showing an intact muscularis mucosae. (E) The lesion was completely removed via ESD. 0-IIa+IIc lesion on the gastric antrum of the remnant stomach. (A) White light imaging shows a superficial elevation with mild central depression. (B) BLI+ME showing an abnormal vascular network. (C) EUS showing an intact muscularis mucosae. Given the patient's prior history of synchronous multifocal early gastric carcinomas treated with proximal gastrectomy, the multifocal distribution of the current lesions, and the 9-year interval between the two episodes, a diagnosis of metachronous multifocal early gastric cancer was established. A 14C-urea breath test for H. pylori was negative, and contrast-enhanced abdominal computed tomography showed no evidence of lymph node or distant metastasis. After multidisciplinary team discussion, a comprehensive review of current clinical guidelines, and consideration of the patient’s preference, we performed EMR for the lesions on the anterior wall of the remnant stomach and on the gastric antrum, and ESD for the lesion on the lesser curvature of the remnant stomach (Figure 2E). Postoperative pathological examination revealed three lesions of well-differentiated tubular adenocarcinoma all confined to the mucosa. Horizontal and vertical margins were negative, with no lymphovascular or perineural invasion. Immunohistochemistry demonstrated proficient mismatch repair (pMMR), with intact nuclear expression of MLH1, PMS2, MSH2, and MSH6 in all three lesions. The background mucosa showed chronic atrophic gastritis with intestinal metaplasia. The final stage was pT1aN0M0 (Figures 4A–F), and all three lesions achieved curative endoscopic resection meeting eCuraA-equivalent criteria (9). The patient recovered uneventfully and was discharged in good condition. Long-term endoscopic surveillance is ongoing. Histopathological features of three metachronous gastric lesions resected in 2026 (HE staining). All three lesions were histologically confirmed as well-differentiated tubular adenocarcinoma confined to the mucosa (pT1aN0M0). (A, B) Lesion on the anterior wall of the remnant stomach. (A) The lesion shows clear demarcation from adjacent normal mucosa, with mildly to moderately crowded neoplastic glands. Most glands retain regular contours, lined by single-layer or pseudostratified columnar cells. The nuclei are rod-shaped and hyperchromatic with evenly distributed chromatin, positioned at the base of epithelial cells with intact polarity. (B) High magnification of (A), showing focal prominent architectural atypia characterized by irregularly branched and dilated glands. (C, D) Lesion on the lesser curvature of the remnant stomach. (C) The lesion is well demarcated from surrounding mucosa, with mildly to moderately crowded neoplastic glands. (D) Magnified view of (C) Some areas show regular glandular structures with basally located rod-shaped hyperchromatic nuclei and preserved polarity; other regions present severe architectural atypia. These atypical glands are lined by cuboidal cells with enlarged round-to-oval hyperchromatic nuclei, coarse granular chromatin and prominent nucleoli. (E, F) Lesion on the remnant gastric antrum. (E) This lesion features sharply demarcated borders and mildly crowded neoplastic glands with regular outlines, lined by single-layer or pseudostratified epithelium with basally positioned polarized rod-shaped hyperchromatic nuclei and evenly distributed chromatin. (F) High magnification of (E), demonstrating widespread severe architectural atypia; cuboidal tumor cells contain enlarged round-to-oval hyperchromatic nuclei with coarse granular chromatin and conspicuous nucleoli. Scale bars: 200 μm (A, C, E); 50 μm (B, D, F). Discussion Synchronous multifocal gastric cancer Synchronous multifocal gastric cancer is defined as the presence of two or more independent tumors occurring simultaneously or within 6 months in different locations of the stomach. Each lesion must be pathologically confirmed as carcinoma, and the tumors are spatially separated by segments of histologically normal gastric wall without mutual continuity (10). Although complete original gastroscopic images from the initial presentation are unavailable, the distribution of lesions across multiple regions of the stomach and postoperative pathology indicating multifocal, mutually independent lesions support a clinical diagnosis of synchronous multifocal gastric cancer. It should be noted that the lack of original endoscopic imaging data imposes certain retrospective limitations on this judgment. Synchronous multifocal gastric cancers account for a relatively small proportion of all gastric cancers, but they have important clinical implications. Previous studies have reported that synchronous multifocal gastric cancers constitute approximately 6%–14% of all gastric cancers (11), although some retrospective analyses suggest that the actual proportion may be lower (12, 13). Eom et al. identified older age, male sex, family history of cancer, and tumor location in the upper third of the stomach as risk factors for synchronous multifocal gastric cancer (14). Multiple studies have demonstrated that multifocal gastric cancers predominantly present as early gastric cancer and that, compared with solitary gastric cancer, there are no significant differences in overall survival or clinicopathological parameters, including lymphovascular invasion, histologic differentiation, and lymph node metastasis (15, 16). In the present case, multifocal lesions were identified sequentially: the 2017 lesions were HGIN (pTis), and the 2026 lesions were well-differentiated tubular adenocarcinomas confined to the mucosa; all showed favorable histology without lymphovascular, perineural, or lymph node involvement. These clinicopathological features are consistent with previous reports of multifocal gastric cancer (17, 18) and support the current consensus that minimally invasive endoscopic therapy represents an effective curative strategy for multifocal early gastric cancer with favorable histologic characteristics. Lessons from long-term endoscopic surveillance One of the most critical concerns regarding synchronous multifocal gastric cancers is how to avoid missed diagnoses. Even experienced endoscopists at university-affiliated hospitals have been reported to have a diagnostic miss rate of 14.7% for synchronous multifocal gastric cancer (5). A meta-analysis showed that ESD achieves outcomes comparable to gastrectomy for early gastric cancer in terms of overall, disease-specific, and disease-free survival. However, patients treated with ESD exhibit higher incidences of recurrent, synchronous, and metachronous cancers (19). The endoscopic findings of early gastric cancer are often subtle, and the missed diagnosis rate is particularly high for small and flat lesions (20). Therefore, once a gastric cancer lesion is detected, in addition to precise assessment of the primary lesion, the entire stomach must be systematically examined. Particular attention should be paid to perilesional regions and mucosal areas at high risk, such as those with atrophic changes or intestinal metaplasia. The use of electronic chromoendoscopy and magnifying endoscopy can improve diagnostic accuracy and help minimize missed lesions. In our patient, multiple ulcerative lesions were identified at the initial presentation in 2017. Previous studies have reported that ulcerative gastric cancers tend to be more aggressive than non-ulcerative cancers (21), and at that time his lesions did not meet the absolute indications for endoscopic resection of early gastric cancer under the prevailing guidelines (22). Although the lesions fell within the expanded indications for endoscopic resection, endoscopic treatment was considered less favorable given the multifocal distribution and the family history of cancer; local gastric resection (proximal one-third gastrectomy) was therefore selected. Fortunately, final pathology revealed multifocal high-grade intraepithelial neoplasia, and careful long-term endoscopic follow-up subsequently detected metachronous multifocal early gastric cancers at an early stage. Metachronous gastric cancer and risk factors Metachronous gastric cancer is defined as a second primary gastric cancer that occurs more than 12 months after curative treatment of the initial gastric cancer and is anatomically independent of the primary tumor. When anatomical assessment is inconclusive, molecular clonality analyses may be helpful (8, 23). Our patient underwent regular endoscopic surveillance after the first surgery. Nine years later, three new lesions were detected in the remnant stomach. None showed direct continuity with the previous tumor sites, and imaging studies revealed no evidence of local recurrence or distant metastasis. Pathological examination supported the diagnosis of new superficial lesions. Taken together, these findings are more consistent with metachronous multifocal primary early gastric cancer than with local recurrence or residual carcinoma. The incidence of metachronous gastric cancer typically peaks between 3 and 5 years after proximal gastrectomy, with the risk gradually decreasing beyond 10 years postoperatively (24). A nationwide Japanese survey involving 33,731 cases reported that the incidence of metachronous multiple gastric cancer after various types of gastrectomy ranges from 2.35% to 8.21%, depending on the surgical procedure (25). Another Korean study including 3,045 patients who underwent curative partial gastrectomy for gastric cancer reported a 1.1% overall incidence of metachronous gastric cancer (excluding tumors at the anastomotic site), and all cases involved solitary lesions (26). In contrast, our patient developed metachronous early gastric cancers at multiple sites in the remnant stomach, including the lesser curvature, anterior wall, and antrum. To our knowledge, this specific ‘double multifocal’ phenotype—synchronous multiple lesions at initial diagnosis followed by metachronous multiple lesions after nine years—has rarely been documented in the literature. Established risk factors for metachronous gastric cancer include male sex, smoking, advanced age, H. pylori infection, gastric mucosal atrophy with intestinal metaplasia, and a history of multiple gastric cancers (27, 28). Eradication of H. pylori significantly reduces the risk of metachronous gastric cancer, but this benefit is attenuated in patients with severe gastric atrophy or intestinal metaplasia (29, 30). In the present case, H. pylori eradication was successfully achieved after the initial surgery. Therefore, the metachronous gastric cancers identified during subsequent follow-up are unlikely to be primarily attributable to persistent or recurrent H. pylori infection. A retrospective review of the follow-up records (Table 1) revealed that gastric mucosal atrophy was already documented one year after the initial surgery. A plausible explanation is that the patient may have already had gastric mucosal atrophy and intestinal metaplasia at the time of the initial diagnosis, although the 2017 pathology report did not specifically document the background mucosal status. These precancerous conditions, together with their associated cumulative genetic and epigenetic alterations, can persist after bacterial clearance and constitute a foundation for the long-term risk of gastric carcinogenesis. Table 1Reconstructed timeline of diagnosis, treatment, and follow-up based on available medical records.TimeClinical EventInterventionEndoscopic & Pathological Results2017 (Initial diagnosis)Gastroscopy performed for epigastric painNoneMultiple ulcerative lesions in the gastric fundus and upper body. Pathology: HGIN2017 (Treatment)Proximal gastrectomySurgical resectionPostoperative diagnosis: HGIN, stage pTisN0M02017 (Postoperative)H. pylori eradicationQuadruple therapySuccessful eradication confirmed by 14C-urea breath test2018–2019Surveillance endoscopyEndoscopic monitoringAtrophy of the remnant gastric antrum2020–2023Surveillance endoscopyEndoscopic monitoringAtrophy of remnant antrum and lower gastric body2024–2025Surveillance endoscopyEndoscopic monitoringAtrophy with intestinal metaplasia in remnant antrum and gastric body2026Surveillance endoscopy revealing a lesionMagnifying endoscopy with treatment (EMR/ESD)Three lesions in the remnant stomach. Pathology: well-differentiated tubular adenocarcinoma, Stage pT1aN0M0HGIN, high-grade intraepithelial neoplasia; EMR, endoscopic mucosal resection; ESD, endoscopic submucosal dissection. Reconstructed timeline of diagnosis, treatment, and follow-up based on available medical records. HGIN, high-grade intraepithelial neoplasia; EMR, endoscopic mucosal resection; ESD, endoscopic submucosal dissection. This patient had multiple high-risk factors, indicating that he should be included in a long-term high-risk management program, with intensified endoscopic surveillance and consideration of genetic evaluation. Treatment choice: endoscopic resection vs. completion gastrectomy For this patient, the key therapeutic decision was between endoscopic resection and completion gastrectomy. On the one hand, the current lesions fulfilled the absolute indications for endoscopic treatment of early gastric cancer (31),and previous reports have demonstrated that ESD is feasible and effective for metachronous gastric cancer (32). On the other hand, the combination of prior synchronous multifocal gastric cancer and current metachronous multifocal lesions suggests a persistent carcinogenic susceptibility in the remnant gastric mucosa. From a long-term risk management perspective, total remnant gastrectomy can eliminate the residual gastric mucosa and thereby reduce the future risk of further primary lesions. This approach may be particularly justifiable in young patients or when hereditary predisposition is strongly suspected. However, total gastrectomy is associated with substantial surgical morbidity, impaired nutritional status, and reduced quality of life. After a comprehensive discussion of the potential benefits and risks of both strategies, the patient expressed a strong preference for minimally invasive therapy that preserved gastric function. Considering the small size, favorable histology, and mucosal confinement of the lesions, we regarded endoscopic treatment as an acceptable alternative, provided that intensive surveillance is maintained. Postoperative pathology confirmed curative endoscopic resection of all three lesions meeting eCuraA-equivalent criteria, and the patient remains under close endoscopic follow-up. Genetic evaluation in high-risk gastric cancer Recent studies have shown that defects in MMR gene function lead to the accumulation of genomic mutations and represent a core mechanism underlying microsatellite instability-high (MSI-H) gastric cancer. MSI and MMR dysfunction are also associated with the occurrence of multiple gastric cancers (33, 34). Individuals carrying pathogenic germline variants in MMR genes (i.e., Lynch syndrome) have a markedly increased lifetime risk of developing gastric and other malignancies, including multiple primary tumors (35). MMR/MSI testing and germline genetic testing are of significant clinical importance in the precision diagnosis and treatment of gastric cancer. From an etiological perspective, MMR deficiency is closely associated with hereditary cancer syndromes, and such testing can provide valuable information regarding the tumor's molecular subtype and potential hereditary background. Furthermore, with respect to therapeutic and prognostic implications, the MSI-H/dMMR phenotype carries predictive value for responsiveness to immune checkpoint inhibitors and for long-term outcome (36). Should recurrence or metastasis develop, knowledge of the tumor's MMR/MSI status would be informative for treatment decisions. In our patient, several clinical features raise suspicion for an underlying hereditary cancer predisposition: relatively young age at onset, a first-degree relative who died of colon cancer, and recurrent multifocal gastric cancers involving both synchronous and metachronous lesions. These features would prompt genetic counseling, tumor MMR/MSI testing, and germline multigene panel testing in contemporary clinical practice. Immunohistochemistry showed all lesions to be pMMR, reducing the likelihood of an MMR-deficient tumor pathway (including classic Lynch syndrome) as the underlying mechanism. However, pMMR does not completely exclude the possibility of germline gene mutations. Additionally, other hereditary gastric cancer syndromes cannot be excluded by MMR testing alone (37). From a tumor biology perspective, field cancerization is the most plausible mechanism underlying multifocal gastric carcinogenesis in this case. The presence of chronic atrophic gastritis with intestinal metaplasia in the background mucosa, together with the pMMR status across all three 2026 lesions, is consistent with this interpretation—long-standing H. pylori infection, chronic inflammation, and environmental carcinogens may drive extensive molecular alterations that give rise to multiple independent lesions (38). Nevertheless, the relatively young age at onset and a first-degree family history of colorectal cancer remain clinical red flags for a hereditary tumor syndrome; in the absence of germline testing, a hereditary etiology cannot be excluded and warrants further molecular investigation. In retrospect, the initial clinical management focused primarily on locoregional tumor control, while genetic evaluation was not incorporated in a timely manner. Due to the lack of MSI and germline genetic testing, accurate genetic counseling and individualized cancer risk assessment for first-degree relatives remain challenging. This case highlights that, for early-stage gastric cancer patients with high-risk features—regardless of whether the final etiology points to field cancerization or a hereditary syndrome—a comprehensive evaluation framework integrating H. pylori status assessment, background mucosal pathology analysis, MMR/MSI screening, and genetic counseling when indicated should be established at the time of initial diagnosis, to clarify etiology, guide long-term surveillance, and reduce risks for both the patient and at-risk family members. Clinical pearls Even after curative resection and successful H. pylori eradication, patients with synchronous multifocal early gastric cancer remain at continued risk of metachronous cancer in the remnant stomach; the surveillance window should therefore extend well beyond five years and ideally be lifelong. Even after curative resection and successful H. pylori eradication, patients with synchronous multifocal early gastric cancer remain at continued risk of metachronous cancer in the remnant stomach; the surveillance window should therefore extend well beyond five years and ideally be lifelong. Every surveillance endoscopy should systematically examine the entire stomach, including the remnant and anastomotic regions, with particular attention to atrophic or metaplastic mucosa; electronic chromoendoscopy and magnifying endoscopy improve detection of subtle lesions. Every surveillance endoscopy should systematically examine the entire stomach, including the remnant and anastomotic regions, with particular attention to atrophic or metaplastic mucosa; electronic chromoendoscopy and magnifying endoscopy improve detection of subtle lesions. In young patients with multifocal disease and a family history of cancer, genetic counseling should be recommended regardless of tumor MMR status, because pMMR does not exclude a germline predisposition. In young patients with multifocal disease and a family history of cancer, genetic counseling should be recommended regardless of tumor MMR status, because pMMR does not exclude a germline predisposition. MMR immunohistochemistry can be performed on small endoscopic resection specimens and should be routinely considered when molecular characterization is clinically informative. MMR immunohistochemistry can be performed on small endoscopic resection specimens and should be routinely considered when molecular characterization is clinically informative. Limitations Several limitations of this case report should be acknowledged. First, the nine-year surveillance data were obtained from multiple institutions, and original endoscopic images were not available for all follow-up time points. The longitudinal clinical course was reconstructed retrospectively from available endoscopy reports. Given that standardized endoscopic examination and biopsy protocols were not uniformly applied across the participating institutions, the observed sequence of atrophy, intestinal metaplasia, and subsequent carcinogenesis should be interpreted as a suggestive observation rather than a standardized prospective natural-history documentation. Second, molecular testing was limited. The MMR status of the initial lesions could not be obtained, precluding comparison across different time points and lesions. MSI and germline genetic testing have not been completed. Germline multigene panel testing is currently unavailable at our institution, and the patient has not yet completed referral-based testing owing to financial constraints. Although the pMMR results effectively exclude somatic MMR deficiency, germline genetic testing is irreplaceable for the identification of hereditary syndromes. Third, family-history information was incomplete: the age at colorectal cancer diagnosis in the affected first-degree relative and the cancer history of other family members could not be verified from the available records, which limits the accuracy of hereditary-risk assessment. Conclusion We report a case of synchronous multifocal early gastric cancer treated by proximal one-third gastrectomy, followed 9 years later by the development of metachronous multifocal early gastric cancer in the remnant stomach—a ‘double multifocal’ pattern rarely documented in the literature. The metachronous lesions were successfully treated with minimally invasive endoscopic resection, and a curative result meeting eCuraA-equivalent criteria was achieved. This case indicates that patients with synchronous multifocal gastric cancer may remain at risk of metachronous multifocal gastric cancer during long-term follow-up, despite curative resection. For high-risk patients with a family history of cancer, a history of H. pylori infection, and underlying gastric mucosal atrophy with intestinal metaplasia, long-term, standardized, and meticulous endoscopic surveillance is essential. In young patients with recurrent multifocal lesions, genetic counseling and appropriate molecular testing should be strongly considered to optimize individualized management strategies for both the patient and at-risk relatives.